Every peptide, mapped to the body.

153 peptides, from approved drugs to compounds still in trials, sorted by where they act.

FDA-approved
In clinical trials
Wellness and performance
Cosmetic and topical

Loading the body

FDA-approved

Digestive & weight

Dasiglucagon

EvidenceFDA approved

ClassGlucagon analog

Dasiglucagon is an FDA-approved, ready-to-use glucagon analog for severe low blood sugar. Learn how it works, what it is used for, and its side effects.

Reviewed by: William Maish, MD MBA MPH, Clinical Product Lead
Published: October 5, 2026
Last updated: October 5, 2026

Key takeaway

Dasiglucagon (sold as Zegalogue) is a stable glucagon analog formulated as a ready-to-use injection for the emergency treatment of severe low blood sugar. Because it stays stable in solution, it comes premixed in an autoinjector or prefilled syringe, with no reconstitution needed. It has been FDA-approved in the U.S. since 2021 and is now approved for adults and children with diabetes who weigh at least 20 kg.

At a glance

What it is	A glucagon analog peptide engineered for stability in a ready-to-use liquid
Approved for	Severe hypoglycemia in adults and children with diabetes who weigh at least 20 kg (about 44 pounds)
Key fact	In a phase 3 trial, median time to blood-sugar recovery was 10 minutes versus 40 minutes with placebo
Route	Subcutaneous injection (autoinjector or prefilled syringe)
Evidence strength	FDA approved

What is dasiglucagon?

Dasiglucagon, sold under the brand Zegalogue, is a modified version of glucagon designed to remain stable in a water-based solution. Native glucagon is unstable once dissolved, which is why traditional emergency kits require mixing a powder with liquid at the moment of a crisis; dasiglucagon's amino-acid changes let it be supplied premixed and ready to use. It is an emergency rescue treatment for severe hypoglycemia. It was developed under the codes ZP4207 and ZP-GA-1 and approved in the United States in 2021.

How does dasiglucagon work?

Dasiglucagon activates the same liver glucagon receptor as native glucagon, triggering glycogenolysis and gluconeogenesis so the liver releases glucose and blood sugar rises quickly. Its structural changes do not alter what it does at the receptor; they make the molecule stable enough to be stored as a ready-to-use liquid, which matters in an emergency where every step of mixing and preparation costs time.

That practical advantage is the point of the drug. In its phase 3 trial in adults with type 1 diabetes, dasiglucagon produced a median time to plasma-glucose recovery¹ of 10 minutes versus 40 minutes with placebo, with nearly all patients recovering within 15 minutes. A separate pediatric trial supported its use in children.

Is it FDA-approved?

Yes. Dasiglucagon (Zegalogue) is FDA-approved, and its label has changed since approval:

Date	FDA action	Who it covers
2021	Approved² for severe hypoglycemia in people with diabetes	Ages 6 and up
June 2026	Label replaced the age limit with a weight limit	Adults and children who weigh at least 20 kg (about 44 pounds)

It is available as an autoinjector and a prefilled syringe.

What is dasiglucagon prescribed for?

Dasiglucagon is prescribed as emergency treatment for severe hypoglycemia in adults and children with diabetes who weigh at least 20 kg, typically administered by a caregiver. As with glucagon, it is contraindicated in pheochromocytoma and insulinoma.

What are the side effects?

According to the prescribing information, common side effects include:

Nausea and vomiting
Headache
Diarrhea (in adults)
Injection-site pain

More serious considerations include:

A rise in blood pressure in people with pheochromocytoma
Low blood sugar rebound in people with insulinoma
Serious allergic reactions

More for digestive & weight

Sources: FDA prescribing information for Zegalogue; the phase 3 dasiglucagon trial (Pieber et al., Diabetes Care, 2021, DOI: 10.2337/dc20-2995¹), indexed on PubMed. This document is educational and does not constitute medical advice.